PepGen
The Scientist II, Analytical Development will be a key member of the Analytical Development group at PepGen, focusing on creating transformational therapies for patients with neuromuscular disease. This lab-based role involves leading method development, impurity characterization, and providing analytical support for in-house drug discovery and development activities. The position requires close collaboration with AD/QC and CMC teams to optimize methods for various chemical entities, including peptides and oligonucleotides.
Headquarters
Boston, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
PepGen is a clinical-stage biotechnology company developing peptide-enabled oligonucleotide therapeutics to treat serious genetic neuromuscular and neurological diseases. Their proprietary Enhanced Delivery Oligonucleotide (EDO) platform is designed to improve cellular uptake and tissue targeting of genetic therapies, with programs targeting conditions such as Duchenne muscular dystrophy and myotonic dystrophy. PepGen advances its pipeline through preclinical and clinical development, combining peptide chemistry and nucleic-acid expertise to address the root causes of debilitating genetic diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for PepGen.
Principal Scientist, Analytical Development
Bristol Myers Squibb
Scientist, Analytical Development and Quality Control
Nurix
Associate Director, Analytical Development
Dyne Therapeutics
Senior Research Associate-AD
Piramal Pharma Solutions
Associate Director, Quality Control & Analytical Development
Amylyx Pharmaceuticals
Analytical Chemist II
Eagle Analytical